Ischaemia-modified albumin in pulmonary hypertension

References

• Abboud H, Labreuche J, Meseguer E, Lavallee PC, Simon O, Olivot JM, Mazighi M, Dehoux M, Benessiano J, Steg PG, Amarenco P. (2007). Ischemia modified albumin in acute stroke. Cerebrovasc Dis 23:216–20.
   PubMed Web of Science ®Google Scholar
• Apple FS, Quist HE, Otto AP, Mathews WE, Murakami MM. (2002). Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after marathon race. Clin Chem 48:1097–100.
   PubMed Web of Science ®Google Scholar
• Badesh DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A. (2009). Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55–S66.
   Web of Science ®Google Scholar
• Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, Branham E, Apple FS, Murakami M, Morris DL. (2001). Characteristics of an albumin binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 47:464–70.
   PubMed Web of Science ®Google Scholar
• Cichota LC, Moresco RN, Duarte MM, da Silva JE (2008). Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. J Clin Lab Anal 22:1–5.
   PubMed Web of Science ®Google Scholar
• Consuerga-Sanchez L, Boulas-Mosquera A, Sinha MK, Collinson PO, Gaze DC, Kaski JC. (2008). Ischemia-modified albumin predicts short-term outcome and 1-year mortality in patients attending the emergency department for acute ischemic chest pain. Heart Vessels 23:174–80.
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenes-Sosa A, Samimi-Fard S, Idaira HB. (2009a). Does ischemia-modified albumin add prognostic value to the Thrombolysis in myocardial infarction risk score in patients with ST-segment elevation myocardial infarction treated with primary angioplasty? Biomarkers 14:43–8.
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez A, Kaski JC, Abreu-Gonzalez P, Samimi-Fard S. (2009b). Role of ischemia modified albumin to ST-segment resolution after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. Atherosclerosis 203:576–80.
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzales MJ, Samimi-Fard S, Reiter RJ, Kaski JC. (2008a). Association of ischemia-modified albumin and melatonin in patients with ST-elevation myocardial infarction. Atherosclerosis 199:73–8.
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzales MJ, Samimi-Fard S, Kaski JC. (2008b). Relation of ischemia-modified albumin levels and left ventricular systolic function in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Clin Chim Acta 388:196–9.
   PubMed Web of Science ®Google Scholar
• Dusek J, St’ásek J, Tichy M, Bis J, Gregor J, Vojácek J, Masín V, Polanský P, Brtko M, Cernohorský D. (2006). Prognostic significance of ischemia modified albumin after percutaneous coronary intervention. Clin Chim Acta 367:77–80.
   PubMed Web of Science ®Google Scholar
• Falkensammer J, Stojakovic T, Huber K, Hammerer-Lercher A, Gruber I, Scharnagl H, Fraedrich G, Santner W, Schocke M, Greiner A. (2007). Serum levels of ischemia-modified albumin in healthy volunteers after exercise induced calf-muscle ischemia. Clin Chem Lab Med 45:535–40.
   PubMed Web of Science ®Google Scholar
• Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, Szturmowicz M. (2006). Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129:1313–21.
   PubMed Web of Science ®Google Scholar
• Govender R, De Greef J, Delport R, Becker PJ, Vermaak WJ. (2008). Biological variation of ischemia-modified albumin in healthy subjects. Cardiovasc J Afr 19:141–4.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, Torbicki A. (2004). End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 43(Suppl. 12):48S–55S.
   Web of Science ®Google Scholar
• Kurz K, Voelker R, Zdunek D, Wergeland R, Hess G, Ivandic B, Katus H, Giannitsis E. (2007). Effect of stress-induced reversible ischemia on serum concentrations of ischemia-modified albumin, natriuretic peptides and placental growth factor. Clin Res Cardiol 96:152–7.
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RBet al. (2005). Recommendations for Chamber Quantification: a report from the American Society of Echocardiography’s guidelines and the Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–63.
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. (2000). Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865–70.
   PubMed Web of Science ®Google Scholar
• Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, Januzzi JL, Jesse RL, Kaski JC, Kontos MC, Lefevre G, Mutrie D, Sinha MK, Uettwiller-Geiger D, Pollack CV. (2006). Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 152:253–62.
   PubMed Web of Science ®Google Scholar
• Quiles J, Roy D, Gaze D, Garrido IP, Avanzas P, Sinha M, Kaski JC. (2003). Relation of Ischemia-Modified Albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol 92:322–4.
   PubMedGoogle Scholar
• Roy D, Quiles J, Sinha M, ldama G, Gaze D, Kaski JC. (2004a). Effect of direct-current cardioversion on ischemia-modified albumin in patients with atrial fibrillation. Am J Cardiol 93:366–8.
   PubMed Web of Science ®Google Scholar
• Roy D, Quiles J, Sinha M, Floros D, Gaze D, Collinson P, Baxter GF, Kaski JC. (2004b). Effect of radiofrequency catheter ablation on the biochemical marker ischemia-modified albumin. Am J Cardiol 94:234–6.
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Georgiadou P, Koutelou M, Sklavainas I, Panagiotakos D, Voudris V (2009a). Ischaemia-modified albumin in dilated cardiomyopathy. Ann Clin Biochem 46:241–3.
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Georgiadou P, Panagiotakos D, Alivizatos P, Voudris V. (2009b). Ischemia modified albumin following coronary arterial bypass grafting. Biomarkers 14:38–42.
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Georgiadou P, Panagiotakos D, Kyrzopoulos S, Tsiapras D, Voudris V, Kremastinos DT. (2008a). Ischemia modified albumin in relation to pharmacologic stress testing in coronary artery disease. Clin Chim Acta 396:58–61.
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Georgiadou P, Panagiotakos D, Livanis EG, Theodorakis GN, Kremastinos DT. (2008b). The ischemia modified albumin in relation to pacemaker and defibrillator implantation. Pacing Clin Electrophysiol 31:83–7.
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Georgiadou P, Panagiotakos D, Livanis EG, Theodorakis GN, Kremastinos DT. (2007). Ischaemia modified albumin in radiofrequency catheter ablation. Europace 9:127–9.
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Georgiadou P, Theodorakis GN, Kremastinos DT. (2006). Ischemia-modified albumin in relation to exercise stress testing. J Am Coll Cardiol 48:2482–4.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. (2009). Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43–S54.
   PubMed Web of Science ®Google Scholar
• Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. (2003). Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 107:2403–5.
   PubMed Web of Science ®Google Scholar
• Torbicki A, Kurzyna M, Kuca P, Fijałkowska A, Sikora J, Florczyk M, Pruszczyk P, Burakowski J, Wawrzyńska L. (2003). Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 108:844–8.
   PubMed Web of Science ®Google Scholar
• Turedi S, Gunduz A, Mentese A, Karahan SC, Yilmaz SE, Eroglu O, Nuhoglu I, Turan I, Topbas M. (2007). Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med 25:770–3.
   PubMed Web of Science ®Google Scholar
• Turedi S, Gubduz A, Mentese A, Topbas M, Karahan SC, Yeniocak S, Turan I, Eroglu O, Ucar U, Karaca Y, Turkmen S, Russell RM. (2008). The value of ischemia-modified albumin compared with d-dimer in the diagnosis of pulmonary embolism. Resp Res 9:49.
   PubMed Web of Science ®Google Scholar
• Turedi S, Patan T, Gunduz A, Mentese A, Tekinbas C, Topbas M, Karahan SC, Yulug E, Turkmen S, Ucar U. (2009). Ischemia-modified albumin in the diagnosis of pulmonary embolism: an experimental study. Am J Emerg Med 27:635–40.
   PubMed Web of Science ®Google Scholar
• Van der Zee PM, Verberne HJ, Straalen JP, Sanders GT, Van Eck-Smit BL, de Winter RJ, Fischer JC. (2005). Ischemia-modified albumin measurements in symptom-limited exercise myocardial perfusion scintigraphy reflect serum albumin concentrations but not myocardial ischemia. Clin Chem 51:1744–6.
   PubMed Web of Science ®Google Scholar
• Warwick G, Thomas PS, Yates DH. (2008). Biomarkers in pulmonary hypertension. Eur Resp J 32:503–12.
   PubMed Web of Science ®Google Scholar